The estimated Net Worth of Capital Management, Llc Aquilo is at least $69.9 Milión dollars as of 21 July 2020. Capital Aquilo owns over 1,900,000 units of Pieris Pharmaceuticals Inc stock worth over $64,285,020 and over the last 4 years Capital sold PIRS stock worth over $5,605,000.
Capital has made over 1 trades of the Pieris Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Capital sold 1,900,000 units of PIRS stock worth $5,605,000 on 21 July 2020.
The largest trade Capital's ever made was selling 1,900,000 units of Pieris Pharmaceuticals Inc stock on 21 July 2020 worth over $5,605,000. On average, Capital trades about 1,900,000 units every 0 days since 2020. As of 21 July 2020 Capital still owns at least 3,675,530 units of Pieris Pharmaceuticals Inc stock.
You can see the complete history of Capital Aquilo stock trades at the bottom of the page.
Capital's mailing address filed with the SEC is ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO, CA, 94129.
Over the last 9 years, insiders at Pieris Pharmaceuticals Inc have traded over $24,745,707 worth of Pieris Pharmaceuticals Inc stock and bought 1,154,000 units worth $3,376,410 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Advisors Llc Orbi Med Capit... a Chau Quang Khuong. On average, Pieris Pharmaceuticals Inc executives and independent directors trade stock every 144 days with the average trade being worth of $4,572,148. The most recent stock trade was executed by Capital Management, Llcadar... on 9 August 2024, trading 6,000 units of PIRS stock currently worth $92,340.
pieris pharmaceuticals is a clinical stage biotechnology company that discovers and develops anticalin-based drugs to target validated disease pathways in a unique and transformative way. our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled anticalin to treat uncontrolled asthma and a half-life-optimized anticalin to treat anemia. proprietary to pieris, anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. our libraries of more than 100 billion different anticalin proteins have repeatedly delivered drug candidates binding to a very broad spectrum of therapeutic targets. pieris has established a diverse pipeline of anticalin therapeutics for a number of different indications and has r&d collaborations with roche
Pieris Pharmaceuticals Inc executives and other stock owners filed with the SEC include: